scholarly journals The Protective Role of Smad7 in Diabetic Kidney Disease: Mechanism and Therapeutic Potential

Diabetes ◽  
2010 ◽  
Vol 60 (2) ◽  
pp. 590-601 ◽  
Author(s):  
H. Y. Chen ◽  
X. R. Huang ◽  
W. Wang ◽  
J. H. Li ◽  
R. L. Heuchel ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Therapeutic Potential ◽  
Protective Role ◽  
Disease Mechanism ◽  
Diabetic Kidney

scholarly journals Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease

2021 ◽  
Vol 14 (8) ◽  
pp. 751
Author(s):  
Swayam Prakash Srivastava ◽  
Rohit Srivastava ◽  
Subhash Chand ◽  
Julie E. Goodwin
Keyword(s):  
Kidney Disease ◽  
Viral Entry ◽  
Diabetic Kidney Disease ◽  
Thrombus Formation ◽  
Renin Angiotensin System ◽  
Cell Types ◽  
Protective Role ◽  
Kidney Cells ◽  
Diabetic Kidney

The present review describes COVID-19 severity in diabetes and diabetic kidney disease. We discuss the crucial effect of COVID-19-associated cytokine storm and linked injuries and associated severe mesenchymal activation in tubular epithelial cells, endothelial cells, and macrophages that influence neighboring cell homeostasis, resulting in severe proteinuria and organ fibrosis in diabetes. Altered microRNA expression disrupts cellular homeostasis and the renin-angiotensin-system, targets reno-protective signaling proteins, such as angiotensin-converting enzyme 2 (ACE2) and MAS1 receptor (MAS), and facilitates viral entry and replication in kidney cells. COVID-19-associated endotheliopathy that interacts with other cell types, such as neutrophils, platelets, and macrophages, is one factor that accelerates prethrombotic reactions and thrombus formation, resulting in organ failures in diabetes. Apart from targeting vital signaling through ACE2 and MAS, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are also associated with higher profibrotic dipeptidyl transferase-4 (DPP-4)-mediated mechanisms and suppression of AMP-activated protein kinase (AMPK) activation in kidney cells. Lowered DPP-4 levels and restoration of AMPK levels are organ-protective, suggesting a pathogenic role of DPP-4 and a protective role of AMPK in diabetic COVID-19 patients. In addition to standard care provided to COVID-19 patients, we urgently need novel drug therapies that support the stability and function of both organs and cell types in diabetes.

scholarly journals Role of TGF-alpha in the progression of diabetic kidney disease

2017 ◽  
Vol 312 (6) ◽  
pp. F951-F962 ◽  
Author(s):  
Josef G. Heuer ◽  
Shannon M. Harlan ◽  
Derek D. Yang ◽  
Dianna L. Jaqua ◽  
Jeffrey S. Boyles ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Renal Disease ◽  
Neutralizing Antibodies ◽  
Diabetic Kidney Disease ◽  
Transforming Growth Factor ◽  
Renin Angiotensin System ◽  
Neutralizing Antibody ◽  
Diabetic Kidney

Transforming growth factor-alpha (TGFA) has been shown to play a role in experimental chronic kidney disease associated with nephron reduction, while its role in diabetic kidney disease (DKD) is unknown. We show here that intrarenal TGFA mRNA expression, as well as urine and serum TGFA, are increased in human DKD. We used a TGFA neutralizing antibody to determine the role of TGFA in two models of renal disease, the remnant surgical reduction model and the uninephrectomized (uniNx) db/db DKD model. In addition, the contribution of TGFA to DKD progression was examined using an adeno-associated virus approach to increase circulating TGFA in experimental DKD. In vivo blockade of TGFA attenuated kidney disease progression in both nondiabetic 129S6 nephron reduction and Type 2 diabetic uniNx db/db models, whereas overexpression of TGFA in uniNx db/db model accelerated renal disease. Therapeutic activity of the TGFA antibody was enhanced with renin angiotensin system inhibition with further improvement in renal parameters. These findings suggest a pathologic contribution of TGFA in DKD and support the possibility that therapeutic administration of neutralizing antibodies could provide a novel treatment for the disease.

The Role of Insulin-like Growth Factors in Diabetic Kidney Disease

1993 ◽  
Vol 22 (5) ◽  
pp. 722-726 ◽  
Author(s):  
Derek LeRoith ◽  
Haim Werner ◽  
Moshe Phillip ◽  
Charles T. Roberts
Keyword(s):  
Growth Factors ◽  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Diabetic Kidney ◽  
Insulin Like Growth Factors

scholarly journals MicroRNAs in Diabetic Kidney Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Rong Li ◽  
Arthur C. K. Chung ◽  
Xueqing Yu ◽  
Hui Y. Lan
Keyword(s):  
Kidney Disease ◽  
Messenger Rna ◽  
Diabetic Kidney Disease ◽  
Target Genes ◽  
Therapeutic Potential ◽  
Expression Patterns ◽  
Diagnostic Tools ◽  
Diabetic Kidney ◽  
Functional Studies ◽  
Gene Expression Studies

Rapid growth of diabetes and diabetic kidney disease exerts a great burden on society. Owing to the lack of effective treatments for diabetic kidney disease, treatment relies on drugs that either reduces its progression or involve renal replacement therapies, such as dialysis and kidney transplantation. It is urgent to search for biomarkers for early diagnosis and effective therapy. The discovery of microRNAs had lead to a new era of post-transcriptional regulators of gene expression. Studies from cells, experimental animal models and patients under diabetic conditions demonstrate that expression patterns of microRNAs are altered during the progression of diabetic kidney disease. Functional studies indicate that the ability of microRNAs to bind 3′ untranslated region of messenger RNA not only shows their capability to regulate expression of target genes, but also their therapeutic potential to diabetic kidney disease. The presence of microRNAs in plasma, serum, and urine has been shown to be possible biomarkers in diabetic kidney disease. Therefore, identification of the pathogenic role of microRNAs possesses an important clinical impact in terms of prevention and treatment of progression in diabetic kidney disease because it allows us to design novel and specific therapies and diagnostic tools for diabetic kidney disease.

Role of Glycyrrhizin in the Reduction of Inflammation in Diabetic Kidney Disease

Nephron ◽  
2017 ◽  
Vol 137 (2) ◽  
pp. 137-147 ◽  
Author(s):  
Vikram Thakur ◽  
Syeda Nargis ◽  
Mayra Gonzalez ◽  
Swetak Pradhan ◽  
Daniel Terreros ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Diabetic Kidney Disease ◽  
Diabetic Kidney
Sign in / Sign up

Export Citation Format

Share Document